pharma · Metachromatic Leukodystrophy (MLD) · Mucopolysaccharidosis type I, Hurler Syndrome
ORCHARD THERAPEUTICS
Orchard Therapeutics (Netherlands) B.V.
Orchard Therapeutics (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis type I, Hurler Syndrome, Mucopolysacchari
London, GB HQ
12 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 12
- Programs
- 5
- Drugs
- 12
- Patents
- 0
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion
Phase 2 · small molecule · Metachromatic Leukodystrophy (MLD)
Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion for Metachromatic Leukodystrophy (MLD) is a Phase 2 program (small_molecule) at Orchard Therapeutics (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).
Internal code 201222
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Orchard Therapeutics (Netherlands) B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metachromatic Leukodystrophy (MLD)
- Status
- active
- Trials
- 1